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Acquired immunodeficiency syndrome caused by HIV-1 or
HIV-2, affects 35.3 million people worldwide. Nine HIV-2
subtypes originating from sooty mangabeys in West Africa
have been described. Subtypes A and B are epidemic while
C to I are crossovers that are known in single persons.
HIV-2F is an exception among non-epidemic subtypes,
being pathogenic and found in two persons, both from
Northern Sierra Leone, suggesting transmissibility. Very
little data are published concerning the distribution and
prevalence of HIV2 in Northern Sierra Leone despite a new
pathogenic HIV2 emerging from this region. Data on ART
treatment coverage is also lacking.
Subjects presenting for voluntary HIV test and those
referred by healthcare providers were enrolled following
informed consent. This represents a targeted, higher risk
population than the general population. Commercial
HIV1/2 rapid tests were used in the field. PCR and NGS
methods are being used to determine prevalence of newly
emerging HIV-2F. A questionnaire was administered to
collect demographic information and treatment history in
those testing positive.
Currently the prevalence of HIV in the targeted sample
population is 5.98%. Interestingly, when compared to the
last published data on HIV-2 in the region, prevalence has
increased by a factor of 32, from 0.021 to 0.68%. 77% of
HIV positive persons were newly identified cases. Of those
previously testing HIV positive, only 41% were currently
on treatment compared to 61% ART coverage in HIV
positive persons in low and middle-income countries
globally.
Our data indicate the prevalence of HIV has increased
in Sierra Leone since the civil war. Further data are
needed to conclusively show prevalence changes of HIV
in Northern Sierra Leone on a population level. The data
also show that ART treatment rates in Northern Sierra
Leone are significantly lower than the global average
highlighting the need for improved case identification
and treatment provision in this resource poor setting.
Sequencing of HIV positive samples to determine the
subtype is in process. This study provides a basis for
further population based study of the HIV strains circu-
lating in Northern Sierra Leone.
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